Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talimogene Laherparepvec in Japanese Advanced Melanoma
NCT03064763Phase 1Completed
- Sponsor
- Amgen
- Start
- Mar 2017
- Primary completion
- Aug 2020
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talimogene laherparepvec in Malignant Melanoma (MM), sponsored by Amgen. Primary endpoints: Dose Limiting Toxicities and Durable Response Rate. Started Mar 2017; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT03064763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03064763.